PURPOSE: To compare the antiviral effect of a peptide derived from human apolipoprotein E (1% apoEdp) with 1% trifluorothymidine against HSV-1 thymidine kinase (TK)-positive (HSV-1 McKrae) and with 3% foscarnet against HSV-1 TK-negative (KOS background) in the rabbit eye model of acute HSV-1 epithelial keratitis. MATERIALS AND METHODS: Topical treatment began three days post-infection and continued for five days. Rabbits were treated 5 times per day with 1% apoEdp, 1% trifluorothymidine, 3% foscarnet, or PBS. Slit lamp examination was performed on a masked basis from post-infection days 3-10 to determine the severity of epithelial keratitis. RESULTS: Topical treatment with 1% apoEdp was as effective as 1% trifluorothymidine against TK-positive and 3% foscarnet against TK-negative HSV-1 epithelial keratitis. CONCLUSIONS: ApoEdp 1% has efficacy for the topical treatment of TK-positive and TK-negative ocular herpes in the rabbit eye model. Thus, apoEdp has the potential to be used for treatment of keratitis caused by TK mutants.
PURPOSE: To compare the antiviral effect of a peptide derived from humanapolipoprotein E (1% apoEdp) with 1% trifluorothymidine against HSV-1 thymidine kinase (TK)-positive (HSV-1 McKrae) and with 3% foscarnet against HSV-1 TK-negative (KOS background) in the rabbit eye model of acute HSV-1 epithelial keratitis. MATERIALS AND METHODS: Topical treatment began three days post-infection and continued for five days. Rabbits were treated 5 times per day with 1% apoEdp, 1% trifluorothymidine, 3% foscarnet, or PBS. Slit lamp examination was performed on a masked basis from post-infection days 3-10 to determine the severity of epithelial keratitis. RESULTS: Topical treatment with 1% apoEdp was as effective as 1% trifluorothymidine against TK-positive and 3% foscarnet against TK-negative HSV-1 epithelial keratitis. CONCLUSIONS:ApoEdp 1% has efficacy for the topical treatment of TK-positive and TK-negative ocular herpes in the rabbit eye model. Thus, apoEdp has the potential to be used for treatment of keratitis caused by TK mutants.
Authors: M Labetoulle; P Auquier; H Conrad; A Crochard; M Daniloski; S Bouée; A El Hasnaoui; J Colin Journal: Ophthalmology Date: 2005-05 Impact factor: 12.079
Authors: K R Wilhelmus; L Gee; W W Hauck; N Kurinij; C R Dawson; D B Jones; B A Barron; H E Kaufman; J Sugar; R A Hyndiuk Journal: Ophthalmology Date: 1994-12 Impact factor: 12.079
Authors: Partha S Bhattacharjee; Donna M Neumann; Timothy P Foster; Christian Clement; Gyanendra Singh; Hilary W Thompson; Herbert E Kaufman; James M Hill Journal: Invest Ophthalmol Vis Sci Date: 2008-05-30 Impact factor: 4.799
Authors: Lena J Al-Dujaili; Patrick P Clerkin; Christian Clement; Harris E McFerrin; Partha S Bhattacharjee; Emily D Varnell; Herbert E Kaufman; James M Hill Journal: Future Microbiol Date: 2011-08 Impact factor: 3.165
Authors: James M Hill; Ethan M Stern; Partha S Bhattacharjee; Daniel Malamud; Christian Clement; Paulo Rodriguez; Walter J Lukiw; Augusto C Ochoa; Timothy P Foster; Cruz Velasco; Harris E McFerrin Journal: Antiviral Res Date: 2013-07-13 Impact factor: 5.970
Authors: Partha S Bhattacharjee; Tashfin S Huq; Tarun K Mandal; Richard A Graves; Syed Muniruzzaman; Christian Clement; Harris E McFerrin; James M Hill Journal: PLoS One Date: 2011-01-06 Impact factor: 3.240
Authors: Partha S Bhattacharjee; Tashfin S Huq; Valencia Potter; Anna Young; Ian R Davenport; Richard Graves; Tarun K Mandal; Christian Clement; Harris E McFerrin; Syed Muniruzzaman; Shubha K Ireland; James M Hill Journal: PLoS One Date: 2012-12-19 Impact factor: 3.240